|
|
Blood, 1 April 2007, Vol. 109, No. 7, pp. 2759-2766.
Prepublished online as a Blood First Edition Paper on November 28, 2006; DOI 10.1182/blood-2006-07-035709.
Previous Article | Next Article 
Submitted July 14, 2006
Accepted November 17, 2006
Intensified CHOP of 12-weeks duration (I-CHOP) plus G-CSF compared with standard CHOP of 24-weeks duration (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin's Lymphoma. A phase III trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)
Leo F Verdonck*, Annelise Notenboom, Daphne D de Jong, Marius A MacKenzie, Gregor E.G. Verhoef, Mark H.H. Kramer, Gert J Ossenkoppele, Jeanette K Doorduijn, Pieter Sonneveld, and Gustaaf W van Imhoff
University Medical Center, Netherlands
HOVON Data Center, Erasmus Medical Center, Netherlands
Netherlands Cancer Institute, Netherlands
University Hospital Gasthuisberg, Belgium
Meander Medical Center, Netherlands
VU Medical Center, Netherlands
Erasmus Medical Center, Netherlands
* Corresponding author; email: l.f.verdonck{at}umcutrecht.nl.
Optimal dose and timing of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy for aggressive non-Hodgkin's lymphoma (NHL) is still an unresolved issue. We assessed whether dose intensifications with cyclophosphamide and doxorubicin might improve outcome in younger patients with intermediate-risk aggressive NHL. Previously untreated patients were assigned to receive either 8 courses of standard CHOP (n=239) or 6 courses of intensified (I)-CHOP (n= 238). Although there was a tendency in favour of I-CHOP for overall survival (OS), disease-free survival (DFS), and event-free survival (EFS), the differences were not significant .However, although these analyses were not planned, when the intermediate-risk group was divided into low-intermediate and high-intermediate risk patients according to the International Prognostic Index (IPI), low-intermediate risk patients had improved 6 year OS (67% versus 52% ; p=0.05), DFS (58% versus 45% ; p=0.06), and EFS ( 41 % versus 30%; p=0.21) when they were treated with I-CHOP compared with standard CHOP. On the other hand, high-intermediate risk patients seem to have no benefit of I-CHOP. Although clinically relevant side-effects occurred more often in the I-CHOP arm, treatment-related mortality was similar. These data suggest that I-CHOP might be preferable to standard CHOP in younger patients with low-intermediate risk aggressive NHL.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
E. Derenzini, M. P. Fina, V. Stefoni, C. Pellegrini, F. Venturini, A. Broccoli, L. Gandolfi, S. Pileri, S. Fanti, E. Lopci, et al.
MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients
Ann. Onc.,
October 27, 2009;
(2009)
mdp455v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H.A. Azim, L. Santoro, R.G. Bociek, S. Gandini, R.A. Malek, and H.A. Azim Jr
High dose intensity doxorubicin in aggressive non-Hodgkin's lymphoma: a literature-based meta-analysis
Ann. Onc.,
October 22, 2009;
(2009)
mdp425v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. H. Wilson, K. Dunleavy, S. Pittaluga, U. Hegde, N. Grant, S. M. Steinberg, M. Raffeld, M. Gutierrez, B. A. Chabner, L. Staudt, et al.
Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers
J. Clin. Oncol.,
June 1, 2008;
26(16):
2717 - 2724.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. P. Canellos
What Constitutes "Improved Prognosis"?
J. Clin. Oncol.,
April 20, 2008;
26(12):
1913 - 1914.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Morel, P. Gaulard, C. Gisselbrecht, C. Ferme, G. Salles, H. Tilly, J. Briere, M. C. Copin, P. Lederlin, O. Hermine, et al.
Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2
Ann. Onc.,
March 1, 2008;
19(3):
560 - 565.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|